We are pleased that our development milestones continue to meet our expectations. We have shown great adoption of ImmunoPulse with the clinical centers enrolling in this Phase II clinical trial for advanced-stage melanoma patients," said Punit Dhillon, President and CEO of OncoSec Medical. "We are now interested in directing the focus to data analysis and the design of our next studies for the melanoma program, including expanding the adoption across other key centers of excellence."
Should be good data updates next month I believe on the 3 phase II studies. And of course potential partnership news. Only pause I had recently in my positive thinking was the Old Dominion research of using immunopulse with 'other' cancer drugs like PD1 and such. Was that just an odd timing coincidence to add that so soon? Surely they would not have any bad news on the IL-12 drug to have to add this other therapy research so early, I am guessing.